Payment overview · 2025
General Payments
$861.75
50 reported records · 16 companies
Healthcare provider profile · identity verified
Andrew J Collins, DO
Allopathic & Osteopathic Physicians|Family Medicine · OWENSBORO, KY · NPI 1568954501
Verified facts
What the public records show
CMS Open Payments records show Andrew J Collins, DO received $861.75 in general payments during 2025 across 50 reported records.
Novo Nordisk Inc accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $267.21 | 31.0% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $136.46 | 15.8% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $96.03 | 11.1% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.08 | 6.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.55 | 5.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.34 | 4.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.83 | 4.0% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $34.45 | 4.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.57 | 3.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.55 | 2.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.75 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.62 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.29 | 2.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.18 | 1.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.37 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.47 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $861.75 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $139.64 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $97.34 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $96.03 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $91.38 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.71 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.64 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $62.64 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $52.08 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $37.02 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $36.18 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.83 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $34.45 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.57 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $27.99 | 2 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 185 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 188 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
188 | 46 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
185 | 44 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
188 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
81 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 946 | 257 |
| Amlodipine Besylate | Amlodipine Besylate | 646 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 627 | 154 |
| Pantoprazole Sodium | Pantoprazole Sodium | 600 | 170 |
| Losartan Potassium | Losartan Potassium | 489 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 419 | 114 |
| Lisinopril | Lisinopril | 406 | 109 |
| Omeprazole | Omeprazole | 359 | 103 |
| Gabapentin | Gabapentin | 334 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 305 | 94 |
| Duloxetine Hcl | Duloxetine Hcl | 289 | 91 |
| Metformin Hcl | Metformin Hcl | 272 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 264 | 74 |
| Sertraline Hcl | Sertraline Hcl | 260 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 258 | 79 |
| Citalopram Hbr | Citalopram Hydrobromide | 253 | 66 |
| Potassium Chloride | Potassium Chloride | 250 | 63 |
| Trazodone Hcl | Trazodone Hcl | 243 | 68 |
| Simvastatin | Simvastatin | 240 | 68 |
| Furosemide | Furosemide | 234 | 69 |
| Alendronate Sodium | Alendronate Sodium | 213 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 50 |
| Famotidine | Famotidine | 192 | 63 |
| Jardiance | Empagliflozin | 188 | 46 |
| Eliquis | Apixaban | 185 | 44 |
| Metformin Hcl Er | Metformin Hcl | 177 | 46 |
| Atenolol | Atenolol | 175 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 161 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 35 |
| Montelukast Sodium | Montelukast Sodium | 158 | 51 |
| Ezetimibe | Ezetimibe | 157 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 44 |
| Carvedilol | Carvedilol | 153 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 147 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 41 |
| Bupropion Xl | Bupropion Hcl | 141 | 35 |
| Buspirone Hcl | Buspirone Hcl | 140 | 41 |
| Meloxicam | Meloxicam | 138 | 48 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 127 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 40 |
| Spironolactone | Spironolactone | 122 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 28 |
| Allopurinol | Allopurinol | 112 | 30 |
| Donepezil Hcl | Donepezil Hcl | 108 | 23 |
| Januvia | Sitagliptin Phosphate | 107 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 52 |
| Synthroid | Levothyroxine Sodium | 102 | 28 |
| Glipizide | Glipizide | 92 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 23 |
| Ozempic | Semaglutide | 90 | 23 |
| Trulicity | Dulaglutide | 81 | 14 |
| Myrbetriq | Mirabegron | 80 | 15 |
| Memantine Hcl | Memantine Hcl | 79 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 20 |
| Finasteride | Finasteride | 77 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 19 |
| Alprazolam | Alprazolam | 74 | 19 |
| Enalapril Maleate | Enalapril Maleate | 74 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 21 |
| Aripiprazole | Aripiprazole | 70 | 22 |
| Clonazepam | Clonazepam | 70 | 19 |
| Lorazepam | Lorazepam | 69 | 21 |
| Trospium Chloride | Trospium Chloride | 67 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 15 |
| Mirtazapine | Mirtazapine | 61 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 16 |
| Pregabalin | Pregabalin | 58 | suppressed |
| Lovastatin | Lovastatin | 57 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 46 |
| Farxiga | Dapagliflozin Propanediol | 51 | 14 |
| Ondansetron Odt | Ondansetron | 51 | 32 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 12 |
| Chlorthalidone | Chlorthalidone | 48 | 14 |
| Tramadol Hcl | Tramadol Hcl | 46 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 13 |
| Celecoxib | Celecoxib | 44 | 12 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Nifedipine Er | Nifedipine | 40 | 13 |
| Klor-Con M20 | Potassium Chloride | 39 | 15 |
| Temazepam | Temazepam | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Estradiol | Estradiol | 37 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Cephalexin | Cephalexin | 34 | 31 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 16 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Prednisone | Prednisone | 30 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 18 |
| Irbesartan | Irbesartan | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Loperamide | Loperamide Hcl | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 17 |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Digoxin | Digoxin | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Sumatriptan | Sumatriptan | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Bumetanide | Bumetanide | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $861.75 · 50 records | Novo Nordisk Inc | AMYVID, AUSTEDO XR, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, GEMTESA, JARDIANCE, KISUNLA, LEQVIO, MOUNJARO, MYFEMBREE, NEXLETOL, Ozempic, PROLIA, REXULTI, Rybelsus, SHINGRIX, Wegovy, XIFAXAN, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error